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Abstract  
Objective: To report a case of severe infusion reaction during the 
first dose of intravenously administered trastuzumab. 
Methods and Results: Here we present a case of a 53-year-old female 
patient (V. Y) with HER 2 pozitive breast cancer who, after completion of 
primary therapy (mastectomy, radiotherapy and chemotherapy) has 
developed hepatic and thoracic vertebrae metastatic formations. Due to this, 
the staff recommended trastuzumab (Herceptin) and capecitabine (Xeloda) 
for six months, but during the intravenously administered trastuzumab, the 
patient developed a severe infusion reaction manifested with hypertension 
(175/98 mm Hg), shortness of breath, cyanosis, pounding heart, panic attack, 
chills and fever. Trastuzumab is not associated with the adverse events that 
typically occur with chemotherapy, such as alopecia, myelosuppression, and 
severe nausea and vomiting. With the exception of hypersensitivity, which 
has been seen mainly and occasionally with the first infusion, cardiotoxicity 
(principally congestive heart failure) is the most important adverse effect of 
trastuzumab.  
Conclusions: Investigations of trastuzumab in the adjuvant setting require 
careful patient monitoring and stopping rules specified for hypersensitivity 
reactions and cardiotoxicity.  
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Background  
 Trastuzumab (Herceptin, Roche), a humanized monoclonal antibody 
against the extracellular domain of HER2, has been shown to benefit patients 
with HER2-positive metastatic breast cancer. Vogel, Cobleigh, Tripathy, et 
al (2002) and Baselga, Carbonell, Castaneda-Soto NJ, et al (2005) reported 
that trastuzumab is safe and efficacious when administered weekly or every 
three weeks, alone. After a phase III, multinational, randomized controlled 
trial, Slamon, Leyland-Jones, Shak, et al (2001), and after a randomized 
phase II trial, Marty, Cognetti, Maraninchi, et al (2005) reconfirmed its 
efficacy and safety even in combination with chemotherapy. According to 
Bell (2002), trastuzumab is not associated with the adverse events that 
typically occur with chemotherapy, such as alopecia, myelosuppression, and 
severe nausea and vomiting. In prescribing information of Genentech Inc. 
(2005), the most important adverse effect of trastuzumab is cardiotoxicity 
(principally congestive heart failure), whereas hypersensitivity has been seen 
mainly and occasionally with the first infusion. For this reason, 
investigations of trastuzumab in the adjuvant setting require careful patient 
monitoring and stopping rules specified for hypersensitivity reactions and 
cardiotoxicity. 
Hereby we present a case of a female patient with breast cancer 
disease who, after completion of primary therapy (mastectomy, radiotherapy 
and chemotherapy) has developed hepatic and thoracic vertebrae metastatic 
formations, as well as a severe hypersensitivity reaction during the first dose 
of intravenously administered trastuzumab. 
 
Case report 
In May 2013, a 53-year-old female patient (V. Y) with record number 
of 174, showed up at oncology service of UHC “Mother Teresa” in Tirana 
with a mass in the left breast. She was recommended routine laboratory and 
imagery studies. Findings were as follows: a 4 cm nodule with irregular 
borders in left breast (superior-lateral quadrant) and left axillary lymph nodes 
of 1.5 cm; on breast sonography; a 4.5 cm nodule with irregular borders and 
micro calcifications in left breast (superior-lateral quadrant) on 
mammography; a C5 fine needle aspiration (FNA) cytology; normal X-ray of 
thorax and abdomen ultrasound; normal tumor markers (CEA, Ca 15-3). In 
her history of life, the patient reported two normal deliveries, one abortion, 
normal lactation (one year for each child) and no hormonal administrations. 
She also reported being allergic to penicillin and taking medications for 
hypertension. 
The patient had left mastectomy at axillary lymph node dissection-
Modificate Madden, and a good postoperative outcome. Histopathologic 
examination reported: ductal infiltrative carcinoma with an lobular 
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infiltrative component of grade 2 and carcinomatous metastasis in 14 of 16 
examinated lymph nodes, pT2, N3, Mx. Immuno-histochemichal examination 
for hormonal receptors and prognostic markers concluded: ER = 1 %, Pr = 5 
%, HER-2/neu = 3 + and Ki = 67 20 %. The final diagnosis was: left breast 
cancer, T2, N3, M0; she was recommended to a chemo- and radiotherapist 
for further treatment. The medical staff opted for chemotherapy regimen 
(administered as adjuvant treatment postoperatively) 4 AC/ 4 T, plus 
radiotherapy and endocrine therapy (tamoxifen), which has been initiated in 
June 2013. 
After four cycles of chemotherapy, in September 2013, the check-up 
ultrasonography results were: no focal lesions on left thoracic site of 
mastectomy; benign nodule on right breast 6 x 4 mm without axillary 
adenopathy; one 9 mm granulomatous calcification in liver, without evidence 
of secondary formations. Laboratory analysis showed adequate baseline, 
hepatic, renal, and bone marrow function. The staff recommended to 
continue on four cycles with taxane and radiation therapy. 
Besides taxane and radiation therapy, in February 2014, the patient 
initiated endocrine therapy Nolvadex (tamoxifen 20 mg tab.).  Five months 
later, in July 2014, the patient came back to hospital complaining of back 
and shoulder pain. Skeletal scintigraphy detected metastasis in thoracic 
vertebrae T3-T7, wich constituted indication for palliative antalgic 
radiotherapy. She was also given Bondronat (ibandronic acid 50 mg tab.). 
 Three months later the control ultrasonography results were: clear 
right and left thoracic quadrants; no axillary and supraclavicular adenopathy; 
hepatic steatosis, 3-4 hypoechogenic lesions of 15 mm diameter. CT 
confirmed hepatic metastasis and osteolytic lesions on thoracic vertebrae. 
Laboratory analysis detected: CEA = 20. 19 (normal < 6. 5 ng/ml), Ca 15-3 = 
334.8 (normal < 25U/ml) and ALP = 1450 (normal < 270 U/l). The staff 
recommended trastuzumab (Herceptin) and capecitabine (Xeloda) for six 
months. 
Before initiating trastuzumab the patient underwent a transthoracic 
echocardiography with the following results: mild diastolic dysfunction with 
left ventricular ejection fraction (LVEF) 0. 59 (normal > 0. 55). Because of 
allergic to penicillin, before adminstering trastuzumab the patient was given 
diphenhydramine and acetaminophen. Within two minutes of infusion the 
patient developed a severe infusion reaction manifested with hypertension 
(175/98 mm Hg), shortness of breath, cyanosis, pounding heart, panic attack, 
chills and fever. She was given oxygen, diazepam 5 mg/ ml (1 amp), CaCl2 
10 % (2 amp), prednizolone 25 mg/ml (3 amp), dexamethazone 4 mg/ml (2 
amp) and furosemid 10 mg/ml (1 amp). She was stable one hour later. Due to 
this event, the staff had to decide an alternative approach for the next future. 
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In November 2014, the patient initiated another treatment regimen with 
capecitabine, and is doing well with it. 
 
Discussion  
 Yarden and Sliwkowski (2001), as well as Gschwind, Fischer and 
Ullrich (2004) demonstrated that HER2/neu (hereafter referred to as HER2) 
belongs to a family of four transmembrane receptor tyrosine kinases that 
mediate the growth, differentiation, and survival of cells. According to 
Slamon, Godolphin, Jones, et al. (1989), overexpression of the HER2 
protein, amplification of the HER2 gene, or both occur in approximately 15 
to 25 percent of breast cancers, and are associated with aggressive behavior 
in the tumor. The use of trastuzumab is associated with the risks of severe 
and rarely fatal infusion-related reactions (e.g., bronchospasm, dyspnea, 
hypoxia, severe hypotension) generally with the first dose (possibly during 
or immediately following the infusion (Hellmann, 2000, Section, Cautions 
for Herceptin, ¶ 6). In those with acute signs and symptoms the initial 
improvement may be followed by marked clinical deterioration leading to 
further complications. Severe infusion-related reactions may result in death 
within hours of the infusion or up to 1 week after the infusion. On the other 
hand, subsequent infusions may be tolerated following complete recovery, 
typically accompanied by prophylactic treatment (e.g., antihistamines and/or 
corticosteroids); severe reactions may recur despite the use of premedication. 
 
Conclusion 
The most important adverse effect of trastuzumab are cardiotoxicity 
and hypersensitivity reactions. Infusion must be interrupted in patients who 
develop dyspnea or clinically important hypotension. Patients should be 
monitored until signs and symptoms of these effects completely resolve. 
Discontinuance of trastuzumab should be strongly considered in patients 
who develop anaphylaxis, angioedema, or acute respiratory distress 
syndrome (ARDS). 
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